On July 29, 2025, Silo Pharma, Inc. entered into an asset purchase agreement with MAVS Holdings LLC, acquiring certain software and domain names. In consideration for the purchased assets, Silo Pharma issued 750,000 shares of its common stock to MAVS Holdings LLC. The shares were offered and sold in reliance upon Section 4(a)(2) under the Securities Act of 1933. The price per share was not disclosed in the document.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-068740), on July 29, 2025, and is solely responsible for the information contained therein.